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Abstract. Metastatic germ cell tumors (GCT) are curable,
however GCTs refractory to cisplatin-based chemotherapy
have a poor prognosis. This study explores D-type cyclins as
molecular targets in GCTs because all-trans-retinoic acid
(RA)-mediated differentiation of the human embryonal
carcinoma (EC) cell line NT2/D1 is associated with G1 cell
cycle arrest and proteasomal degradation of cyclin D1. RA
effects on D-type cyclins are compared in human EC cells
that are RA sensitive or dually RA and cisplatin resistant
(NT2/D1-R1) and in clinical GCTs that have both EC and
mature teratoma components. Notably, GCT differentiation
was associated with reduced cyclin D1 but increased cyclin D3
expression. RA was shown here to repress cyclin D1 through
a transcriptional mechanism in addition to causing its
degradation. The siRNA-mediated repression of individual
cyclin D species resulted in growth inhibition in both RA
sensitive and resistant EC cells. Only repression of cyclin D1
occurred in vitro and when clinical GCTs mature, implicating
cyclin D1 as a molecular therapeutic target. To confirm this,
the EGFR-tyrosine kinase inhibitor, Erlotinib, was used to
repress cyclin D1. This inhibited proliferation in RA and
cisplatin sensitive and resistant EC cells. Taken together, these
findings implicate cyclin D1 targeting agents for the treatment
of GCTs.
Introduction
Cyclin-dependent kinases (cdks) play a major role in ordered
cell cycle progression and their activity is regulated in a cell
cycle-specific manner by interacting with cyclins, as reviewed
(1). Cyclin D species interact with cdk4 and cdk6. A major
substrate of these complexes is the retinoblastoma (Rb) protein.
Rb is maintained in a hypophosphorylated state through most
of the G1 phase, becoming hyperphosphorylated in late G1,
resulting in release of E2F transcription factors, which in turn
augments expression of genes required for S phase (2). A
further layer of control preventing entry into S phase exists in
the form of cdk inhibitors (CKIs) (3). Thus, the ‘Rb pathway’
represented by cyclin D/cdk4/CKI/Rb constitutes a tightly
controlled G1/S checkpoint, the importance of which is
highlighted by clinical findings that one component of the
pathway is mutated or deregulated in the majority of human
cancers (4). 
Germ cell tumors (GCTs) are the most common carcinomas
of men between the age of 15 and 35. Cure of GCTs is possible
with cisplatin-based chemotherapy, even in disseminated
disease, however, patients refractory to treatment do exist
and innovative strategies for the treatment of these cases
are needed. GCTs can exhibit mature teratoma formation,
indicating in vivo differentiation potential of these tumors.
The exquisite sensitivity of GCTs to chemotherapeutic
agents, spontaneous differentiation patterns and characteristic
chromosomal abnormalities make them invaluable models
for solid tumor biology studies (5). In this study, the human
embryonal carcinoma (EC) cell line NT2/D1 was used to
explore retinoid mediated cell cycle arrest and differentiation
mechanisms. The NT2/D1 line is an attractive model for
the study of GCTs because: a) it carries the isochromosome
12p marker diagnostic of GCTs (6), b) it exhibits unique
immunophenotypic markers for the differentiated and undif-
ferentiated states (7,8) and c) it is pluripotent, differentiating
into a neuronal phenotype and other lineages after RA-treatment
(9,10). The pluripotent nature of NT2/D1 cells provides a
valuable and practical complement to human embryonic stem
cells as an in vitro model of early human development (5,11).
We previously reported that cyclin D1 protein decreases
in NT2/D1 cells after RA-treatment (12). This is associated
with increased cyclin D1 ubiquitination that precedes induction
of differentiation. With this decline, RA-treatment also
arrests cells in the G1 phase of the cycle, blocking further
rounds of DNA synthesis. The RA-resistant NT2/D1-R1 line,
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does not demonstrate growth arrest or accumulate in G1, and
has persistent cyclin D1 over-expression, despite RA-treatment
(12). This strongly implicates a link between cyclin D1 levels
and retinoid-mediated growth suppression. 
Engineered over-expression of a degradation-resistant cyclin
D1 species in NT2/D1 cells delays RA-induced differentiation
and cell cycle arrest (12). The effects of RA-treatment on
D-type cyclins have not been explored comprehensively in
ECs or GCTs. Of the members of the D-type cyclin family
(cyclin D1, cyclin D2 and cyclin D3) cyclin D1 is the most
studied with over-expression documented in diverse tumors
including breast (13-15), parathyroid adenomas (16), and
mantle cell lymphomas (17,18). Cyclin D2 is amplified and
over-expressed in subsets of GCTs (19,20). This is thought to
arise from its location on chromosome 12p. Recently, the
critical region of 12p over-represented in male GCTs was
mapped to a 1750-3000 kb region, which did not include
the cyclin D2 locus (21). Cyclin D2 has been proposed as
involved in GCT development and progression, but not in
response to chemotherapeutic or differentiation agents (20,22).
Cyclin D3 has been studied in male GCTs (23) where an
increase in cyclin D3 levels was noted during differentiation.
Cyclin D3 is elevated at the onset of myogenic terminal
differentiation (24). D-type cyclins differ in their cell tissue
context distribution. Cyclin D1 has been the focus of several
studies describing cdk4-independent properties, including
physical association with transcription factors and coactivators,
as reviewed (25). Distinct functional roles for the different
D-type cyclins likely exist, but redundant effects have also
been noted in D-type cyclin knockout models, as reviewed
(26).
In this study, all three cyclin D species were examined to
compare their expression profiles in differentiation sensitive
as compared to resistant EC cells, as well as in clinical GCTs.
Selective siRNA-mediated repression of individual D-type
cyclins was used to learn if these cyclins had different effects
on EC growth and differentiation. Using paraffin-embedded
sections of ECs that also contained mature teratoma, immuno-
histochemical expression profiles for Ki-67, and D-type
cyclins were examined. Findings presented here reveal that
repression of any cyclin D species is sufficient to arrest growth
of GCTs, but it is cyclin D1 that is preferentially associated
with differentiation-dependent growth arrest in cultured EC
cells and in clinical GCTs. Indeed, an inverse relationship
between cyclin D1 and cyclin D3 expression was found with
GCT differentiation. Taken together, these findings indicate
that pharmacological agents that target cyclin D1 for repression
should be considered for GCT therapy.
Materials and methods
Cell culture conditions. NT2/D1 and NT2/D1-R1 human
EC cells were cultured in high glucose DMEM (Invitrogen,
CA) containing 100 U/ml penicillin, 100 μg/ml streptomycin,
2 mM/l glutamine, and 10% fetal bovine serum at 37˚C under
humidified 5% CO2. For stable expression of luciferase-
expressing constructs, cells were plated at 2x105 cells/well
in 6-well tissue culture plates and were cotransfected with
2.0 μg of luciferase reporter plasmid DNA and 0.5 μg of
pcDNA3.1 (Invitrogen) using a modified calcium phosphate
precipitation technique (12). Cells were exposed to DNA
precipitate for 14-16 h, then washed and trypsinized for
transfer to 10 cm tissue culture plates and treatment with
G418 (500 μg/ml). G418 resistant colonies were harvested
for further analyses. Protein concentrations were determined
using the Bradford assay (Bio-Rad, CA) and luciferase activity
was measured using the Promega (WI) luciferase assay system.
Erlotinib was dissolved in the vehicle dimethyl sulfoxide
(DMSO) at 10 mM. Cells were plated at 1x105 (NT2/D1) and
0.5x104 (NT2/D1-R1) per well in 6-well plates in triplicate.
Erlotinib was added 24 h after cell plating and fresh drug and
media were added after 48 h. Cells were trypsinised and
harvested at 72 h and counted using a hemacytometer. 
RA induction protocol. Western and Northern blot analyses.
RA was dissolved in DMSO as a 10 mM stock solution and
stored in liquid nitrogen. Cells were treated with 10 μM RA.
Total cellular RNA was isolated using TriReagent (Molecular
Research Center, OH). RNA was size-fractionated on a 1%
agarose denaturing gel before transfer to a nylon membrane
(Schleicher and Schuell, NH). Northern filters were hybridized
with probes random-labeled with [32P]-dCTP at 1x106 cpm/ml
in hybridization solution [0.5 M sodium phosphate, pH 7.0,
7% sodium dodecyl sulfate (SDS), 1% bovine serum albumin,
and 1 mM EDTA] at 67˚C overnight. Filters were stringently
washed, as previously described (27). The cDNA probes
used for Northern blot analyses were respectively a 1.1 kb
Hind III restriction endonuclease fragment isolated from
the pRcCMV-cyclin D1-HA vector, a 1.0 kb Hind III/Xba I
restriction endonuclease fragment isolated from the pRcCMV-
cyclin D2 vector and a 1.1 kb Hind III/Xba I restriction endo-
nuclease fragment isolated from the pRcCMV-cyclin D3-HA
vector.
Cells were lyzed in a modified radioimmune precipitation
buffer, as previously described (28). Total protein lysates
were separated by SDS-polyacrylamide gel electrophoresis
and transferred to a nitrocellulose membrane. Antibodies
used individually recognized cyclin D1 (M20), cyclin D2
(C17), cyclin D3 (C16) or actin (C11) (Santa Cruz, CA).
Primary antibodies were detected with horseradish peroxidase
conjugated secondary antibodies (Santa Cruz and Amersham,
IL) and visualized using an enhanced chemiluminescence
system (Amersham).
Heterogeneous nuclear RNA analysis. Total cellular RNA
was isolated as already described and any contaminating DNA
was removed using the DNAfree system (Ambion, Austin,
TX). Reverse transcription (RT) of RNA was performed
using a cDNA synthesis system (Invitrogen). Polymerase
chain reaction (PCR) assays were performed using Taq
polymerase (Invitrogen) according to the manufacturer's
instructions. Cycle number was optimized for each primer
pair. The primer pairs used were: forward primer cyclin D1-
exon1-2 5'-TGTGCTGCGAAGTGGAAACC-3' and reverse
primer cyclin D1-intron1-2 5'-CAAGTTGCAGGGAAGTCT
TAAG-3'; ß-actin forward primer 5'-GCGGGAAATCGTGC
GTGACA-3' and ß-actin reverse primer 5'-AAGGAAGGC
TGGAAGAGTGC-3'; and RAR-ß forward primer 5'-GAGC
GATCCGAGCAGGGTTT-3' and RAR-ß reverse primer
5'-CTGGCAGACGAAGCAGGGTTT-3'.
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siRNA repression of D-type cyclins. Double-stranded siRNA
with 19-nucleotide duplex RNA and a 2-nucleotide deoxy-
thymidine overhang at the 3' region were synthesized
(Dharmacon, CO and Qiagen, CA). Two different siRNAs
were designed to target independently human cyclin D1,
cyclin D2 or cyclin D3 mRNAs. The sequences chosen were
cyclin D1-1 5'-CACCAGCTCCTGTGCTGCG-3', cyclin D1-2
5'-CAAACAGATCATCCGCAAA-3', cyclin D2-1 5'-GTGC
GTGCAGAAGGACATC-3', cyclin D2-2 5'-TAGCCTGCA
GCAGTACCGT-3', cyclin D3-1 5'-GATGCTGGCTTACTG
GATG-3' and cyclin D3-2 5'-GATGGCTCCTCTCAGT
ACT-3'. Firefly luciferase pGL2 siRNA (5'-CGTACGCGGA
ATACTTCGA-3') and scrambled II (scb) (5'-GCGCGCTTT
GTAGGATTCG-3') (Dharmacon) served as siRNA duplex
controls. Transfection of siRNA was performed with
Oligofectamine (Invitrogen), as previously described (29).
To assess effects on cell growth, EC cells were trypsinized
24 h after transfection and plated at 5x104 cells per well in
6-well plates. Triplicate wells were counted for each time-
point post-transfection. Results were expressed as mean ±
standard deviation for a representative experiment. 
Differentiation marker studies. Indirect fluorescence-activated
cell sorter (FACS) analysis to evaluate RA-induced neuronal
differentiation of NT2/D1 cells was performed using estab-
lished techniques (12). Briefly, NT2/D1 cells were harvested
by trypsinization and incubated with monoclonal antibodies
to established EC differentiation markers. The A2B5 anti-
body was isolated from a hybridoma culture and recognizes
a neuronal epitope in RA-treated NT2/D1 cells (ATCC).
SSEA-3 (Developmental Studies Hybridoma Bank, University
of Iowa, USA) recognizes an embryonal antigen, which is
lost as EC cells differentiate (8). Cells were indirectly
assayed with a fluorescein isothiocyanate-conjugated goat
anti-mouse antibody, and fluorescence was measured, as
described (12). 
Immunohistochemistry. Clinical GCT specimens were fixed and
embedded in paraffin using established techniques previously
described (30). The immunohistochemical markers examined
were: cyclin D1, cyclin D3 and Ki-67. Antibodies used to
detect these species were: cyclin D1 (CP236A, Biocare
Medical, CA), cyclin D3 (C17 Santa Cruz) and Ki-67 (clone
MIB1, Dako, Glostrup, Denmark). Use of these clinical GCT
specimens was approved by the Dartmouth College Institutional
Review Board (IRB).
Results
Expression of D-type cyclin expression in retinoid sensitive and
resistant GCT cells. Cyclin D1 protein levels are substantially
repressed after RA-treatment of NT2/D1 cells, but decline
less in RA-resistant NT2/D1-R1 cells (Fig. 1A). Basal levels
of cyclin D1 protein were much higher in the RA resistant
than sensitive EC cells. Cyclin D2 protein levels did not
appreciably change after RA-treatment or increased slightly
and were similar in both retinoid sensitive and resistant EC
cells. Conversely, cyclin D3 protein levels increased markedly
with RA-treatment of NT2/D1 cells, but this was much less
evident in NT2/D1-R1 cells. Basal cyclin D3 protein expression
was also elevated in the retinoid resistant as compared to the
sensitive EC cells. 
Northern blot analyses of D-type cyclins revealed that
after 96 h of RA-treatment, cyclin D1 mRNA levels were
repressed in NT2/D1 cells (Fig. 1B). This was not observed
in NT2/D1-R1 cells where there was no appreciable change
in cyclin D1 mRNA levels and basal levels were lower than
seen in NT2/D1 cells. Appreciable changes in cyclin D2
mRNAs were not seen in either cell line, although the basal
level of cyclin D2 mRNA was much lower in NT2/D1-R1 than
NT2/D1 cells. Cyclin D3 mRNA expression was similar
over the same time course for both cell lines. Comparing
immunoblot and Northern blot analyses for D-type cyclins
between NT2/D1 and NT2/D1-R1 cells established a markedly
different pattern between them. NT2/D1-R1 cells have equal
or lower levels of mRNA for each D-type cyclin, but exhibit
equal or higher protein expression levels. This is most likely
due to increased cyclin D stability in NT2/D1-R1 cells; the
half-life of cyclin D1 is higher in these cells than in the NT2/D1
cells (data not shown). Prior work by others indicates that
cyclin D3 protein stability can increase when it is bound to
the cell cycle inhibitor p27 (31-34) although other researchers
did not find this to be the case (35). The expression of p27
protein increases with RA-treatment of NT2/D1 cells (34,35;
data not shown). 
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Figure 1. Northern and Western blot analyses of cyclin D species before and
after RA-treatment of the human EC cell line NT2/D1 and the RA-resistant
cell line, NT2/D1-R1. (A) Western blot analyses of D-type cyclin species
normalized to total 28S ribosomal RNA. (B) Northern blot analyses of D-type
cyclin species normalized to ß-actin expression.
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Retinoid repression of cyclin D1 mRNA. Although initially due
to an acceleration of cyclin D1 proteasome degradation (12),
longer RA-mediated repression of cyclin D1 is also due to a
decrease in cyclin D1 mRNA expression, as shown in Fig. 1B.
Cyclin D1 mRNA stability did not decrease with RA-treatment
(data not shown). Using hetero-nuclear PCR (hnPCR) assays
the levels of prespliced cyclin D1 mRNA were found to
decrease between 72 and 96 h of RA-treatment (Fig. 2A).
This indicated that the rate of cyclin D1 transcription had
decreased. Of the three cyclin D species more is known about
the control of cyclin D1 transcription in part because this
D-type cyclin is frequently over-expressed in human carcino-
genesis, as reviewed (25). The cyclin D1 promoter contains
multiple domains that respond to oncogenic signals, as
reviewed (25,36). Initial studies with a 1.7 kb region of the
human cyclin D1 promoter (37) reporter construct did not
reveal repression of promoter activity with RA in NT2/D1
cells (data not shown). These experiments were performed by
transiently transfecting this reporter plasmid into NT2/D1 cells,
treating with RA for varying time periods and then assaying
for luciferase activity. However, with stable integration of
the cyclin D1 promoter-luciferase construct into NT2/D1
cells the RA-mediated repression of the cyclin D1 promoter
was evident, as shown in Fig. 2B. Pools of G418-resistant
NT2/D1 cells were treated with RA or the vehicle (DMSO)
and the luciferase activities were normalized to protein
concentration for each time-point. After 72 h of RA-treatment
a significant repression of cyclin D1 promoter activity was
detected. This declined further after 96 and 120 h. A RSV
promoter-luciferase construct was also used to generate a
stable pool of NT2/D1 cells. Treatment of these cells with
RA did not result in repression of luciferase activity as seen
with the cyclin D1 promoter (data not shown).
Repression of D-type cyclins by siRNAs. To determine if
repression of the individual D-type cyclins had growth or
differentiation-inducing effects on EC cells, independent
siRNA duplexes were designed to target each of them. Fig. 3A
and B show respectively Western and Northern blot analyses
of D-type cyclins in response to siRNA transfection. The
siRNAs cyclin D1-1 and cyclin D2-1 specifically repressed
only the desired species, as indicated in this figure and cyclin
FREEMANTLE et al:  D-TYPE CYCLINS AND GERM CELL TUMOR DIFFERENTIATION336
Figure 2. RA-treatment of NT2/D1 cells reduces the rate of cyclin D1
transcription. (A) Hetero-nuclear polymerase chain reaction (hnPCR) assay
of cyclin D1. The cDNA levels were normalized to ß-actin mRNA levels.
RAR-ß PCR demonstrates the expected response to RA-treatment of a known
RA target gene. (B) Cyclin D1 promoter activity measured following
RA-treatment in NT2/D1 cells with a stably integrated cyclin D1 promoter-
luciferase construct. Each luciferase reading was made in triplicate and error
bars represent standard deviation. Shaded bars represent RA treatment and
open bars represent vehicle control. These data are representative results
from at least three independent experiments. 
Figure 3. The effects of siRNA-mediated repression of individual cyclin D-
type species in RA sensitive NT2/D1 cells. (A) Western blot analyses of
D-type cyclins following siRNA treatments specific to individual cyclin D
species in NT2/D1 cells. (B) Northern blot analyses of D-type cyclins after
siRNA treatment specific to individual cyclin D species in NT2/D1 cells.
(C) Cell proliferation analyses of NT2/D1 cells after siRNA treatments.
The siRNAs used were: scrambled (scb) control (■), cyclin D1-1 (❑), cyclin
D2-1 (▲), and cyclin D3-1 (●).
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D3-1 siRNA substantially repressed cyclin D3 expression,
with a minimal repression of cyclin D2 levels also detected.
In proliferation assays, repression of each cyclin D species
also inhibited EC cell growth. The most evident repression
was the siRNA directed against cyclin D3 and this is likely
due to this siRNA duplex repressing both cyclin D3 and
cyclin D2. Cell cycle distribution analyses showed, as expected,
a consistent increase in G1-phase cells after siRNA-mediated
repression of each cyclin D species and bromodeoxyuridine
incorporation analyses revealed a decrease in cells actively
synthesizing DNA (data not shown). Experiments using the
independent cyclin D siRNAs (cyclin D1-2, cyclin D2-2 and
cyclin D3-2) confirmed effects on growth seen with the other
D-type cyclin siRNAs (data not shown), 
These D-type cyclin targeting-experiments were extended
from RA sensitive to resistant EC cells. The siRNA-mediated
repression of cyclin D species in the NT2/D1-R1 cells exhibited
results similar to those observed in NT2/D1 cells (Fig. 4).
Notably, despite deregulation of cyclin D species in NT2/D1-
R1 cells, repression of each D-type cyclin resulted in decreased
proliferation (Fig. 4B). These findings indicate that these EC
cells are still sensitive to growth repression by targeting D-type
cyclins, despite RA resistance.
Differential expression of D-type cyclins in GCTs. Immuno-
histochemical analyses of clinical GCTs were performed
in cases exhibiting both EC and teratoma components.
Findings revealed that EC components of GCTs had a higher
proliferative component than the adjacent teratoma (Fig. 5).
A representative case is shown in Fig. 5. Cyclin D1 immuno-
staining revealed that highly proliferative regions of GCTs
had higher nuclear and cytoplasmic cyclin D1 than the adjacent
teratoma where staining was restricted to the nucleus. In
contrast, cyclin D3 expression was less readily detected than
cyclin D1 in the same cells and was preferentially expressed
within teratomatous elements not exhibiting Ki-67 expression.
A total of 36 samples were analyzed that contained EC and
adjacent teratoma and 34/36 exhibited this pattern of expres-
sion. Thus, an inverse relationship was found to exist between
cyclin D1 and cyclin D3 expression during in vitro and in vivo
GCT differentiation.
Erlotinib treatment of RA sensitive and resistant EC cells
(Fig. 6). Erlotinib treatment resulted in growth inhibition and
repression of cyclin D1 levels in both NT2/D1 and the RA
resistant NT2/ D1-R1 cell line, which is coresistant to cisplatin
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Figure 4. The effects of siRNA-mediated repression of individual cyclin D-
type species in RA resistant NT2/D1-R1 cells. (A) Western blot analyses of
D-type cyclins after siRNA treatments specific to individual cyclin D species
in RA resistant NT2/D1-R1 cells. (B) Cell proliferation analyses of NT2/D1-R1
cells post-siRNA treatment. Numbers over the bars indicate fold increase in
cell number over the 4 days. Each cell count was made in triplicate and error
bars represent standard deviation. The data are representative of at least
three separate experiments. NR1 is pGL2 and NR2 is Scb2 siRNA.
Figure 5. A representative clinical GCT exhibiting both embryonal carcinoma
(EC) and mature teratomatous elements. This case was independently
examined for immunohistochemical expression of cyclin D1, cyclin D3 and
Ki-67. These analyses revealed an inverse relationship between cyclin D1 and
cyclin D3. Black arrow indicates a more proliferative region of teratoma and
the gray arrow indicates a less proliferative region of teratoma based on Ki-67
immunostaining. There is abundant expression of cyclin D1 and repressed
expression of cyclin D3 in EC GCT components. In contrast, cyclin D3
expression is increased in mature teratomatous GCT components.
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(38). Cyclin D2 and cyclin D3 levels were not significantly
changed (data not shown). Erlotinib levels of around 1-2 μM
are clinically achievable and this dose is growth inhibitory
for both cell lines. Specifically targeting cyclin D1 bypasses
the RA and cisplatin resistance mechanism in NT2/D1-R1
cells causing growth suppression. Erlotinib may have clinical
potential in patients who have recurrent disease after
standard cisplatin-containing regimens. 
Discussion
Transcriptional regulation of cyclin D1 has been reported
as an outcome of multiple mitogenic signaling pathways.
Over 50 regulators are cited as acting through the cyclin D1
promoter, as reviewed (36). It was therefore hypothesized
that cyclin D1 mRNA repression following RA-treatment
was most likely due to a decrease in transcription and not a
change in message stability. The hnPCR study verified this
as less unspliced cyclin D1 mRNA was being made after
72-96 h of RA-treatment. Initial transient transfection assays
using luciferase-cyclin D1 promoter constructs did not establish
RA-mediated repression of cyclin D1 promoter activity.
However, when this construct was stably integrated into
the NT2/D1 genome, RA-mediated repression was evident.
Retinoids have been reported to repress cyclin D1 expression
in multiple systems including human hepatoma cells, squamous
cell carcinoma cells, neuroblastoma cells and breast cancer
cells (39-43). In some cases, transcriptional repression has
been found, however, the precise mechanisms engaged could
differ between systems. For example, it was reported that
retinoids suppressed insulin-dependent cell growth and
cyclin D1 gene expression in human breast cancer cells (43),
but that pathway may not be active in all cell contexts. 
In clinical GCTs studied here, cyclin D1 expression
was associated with a high proliferative state such as in EC
elements, whereas cyclin D3 was seen predominantly in
cells which were less proliferative as determined by Ki-67
immunostaining, such as teratomatous elements of the same
GCT. In normal mouse testis cyclin D levels were examined
and cyclin D1 was expressed only in proliferating gonocytes
and spermatogonia whereas cyclin D3 was seen in both
proliferating and quiescent gonocytes during testis develop-
ment (44). Cyclin D3 expression was also seen in terminally
differentiated Sertoli cells, in Leydig cells, and in spermato-
gonia in adult testis. Therefore, in spermatogonia, cyclin D1
and cyclin D3 seem to be involved in cell cycle regulation,
however, cyclin D3 likely plays a distinct role in Sertoli
and Leydig cells. Similarly, in a study of D-type cyclins in
adult human testis and testicular cancer, elevated cyclin D3
levels in the differentiated Leydig cells, in teratoma and in
NT2/D1 cells induced to differentiate with RA were detected
(23). D-type cyclins were not detected in proliferating germ
cells and in contrast to the current study, cyclin D1 was
undetected in NT2/D1 cells. In the current analysis of
cyclin D1 expression in clinical GCTs, it is clearly elevated
in EC compared to teratoma and was readily detected in
NT2/D1 cells. Any discrepancy between these two studies
is likely due to the different antibodies used for cyclin D1
immunodetection. In prior work, cyclin D2 levels were elevated
in most carcinoma in situ GCT lesions studied, implicating a
role for this D-type cyclin in early germ cell tumorigenesis (23).
Levels of cyclin D2 were not significantly different between
EC and teratoma (23) in agreement with the NT2/D1 data,
which is why cyclin D2 was not analyzed in our series of
clinical samples.
Induction of cyclin D3 levels with differentiation has been
reported in other systems including terminal differentiation
of skeletal myoblasts (24). In this study of NT2/D1 cells,
elevation of cyclin D3 was seen only at the protein level
whereas the repression of cyclin D1, although initially due to
accelerated proteolysis (12), was followed by transcriptional
repression of cyclin D1 as shown in Fig. 1. Several groups
have suggested that increases in cyclin D3 levels result from
interactions with the cell cycle inhibitor p27 (31,45). In p27
null murine embryonic stem (ES) cells induced to differentiate
with RA, cyclin D3 expression is much lower when compared
to normal ES cells and these cells also have a higher rate of
apoptosis (46). Together, these findings suggest a role distinct
from the phosphorylation of Rb for the high levels of cyclin D3
expression found in GCTs.
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Figure 6. Erlotinib represses cyclin D1 levels and inhibits cell growth in (A)
RA sensitive and (B) resistant NT2/D1 cells. Western blot analysis of cyclin
D1 after 24 h Erlotinib treatment. Cell counts after 72 h Erlotinib treatment.
Drug administered at 0 and 48 h.
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Specific siRNA-mediated repression of each cyclin D
species causes growth repression, however, it is only cyclin D1
that is repressed when EC cells undergo terminal differen-
tiation following RA-treatment or when clinical GCTs undergo
maturation from EC to mature teratoma. Prior studies have
sought to determine whether the three cyclin D species have
distinct roles in normal growth, development and tumori-
genesis. Transgenic mice engineered to over-express different
D-type cyclins in the breast, under the control of the mouse
mammary tumor viral promoter, produced three distinct
phenotypes. MMTV-cyclin D1 mice produced breast adeno-
carcinoma and squamous cell carcinoma (SCC). MMTV-
cyclin D2 mice show a lack of alveologenesis during pregnancy
and only develop carcinoma at low frequency and MMTV-
cyclin D3 mice only develop SCC (47). Yet, in studies
culminating in the knockout of all three cyclin D species,
murine D-cyclins were dispensable for proliferation of
numerous cell types (26,48). However, these same species
are not dispensable for transformation by RAS- and MYC-
driven oncogenic pathways and therefore they represent
attractive molecular targets for cancer chemoprevention or
therapy (26). Cyclin D1 only knockout mice are resistant
to breast cancers induced by Ras and ErbB2 oncogenes, but
not by Wnt or c-Myc (49). Cyclin D1 deficient mice are also
resistant to gastrointestinal tumors arising in the ApcMin
mice (50). Lack of D-type cyclins or Cdk4 or Cdk6 results
in cells with an impaired ability to enter the cell cycle from
a quiescent state and to respond to activation of mitogenic
signaling pathways, as reviewed (51). Cdk-4-null mouse
embryonic fibroblasts (MEFs) senesce rapidly in culture
(52). The combination of an enhanced ability to enter the
cell cycle, response to mitogenic signaling and avoidance of
senescence can account for the frequent deregulation of this
pathway in cancer. 
In conclusion, of the three D-type cyclins, cyclin D1 is
preferentially repressed as GCTs are induced to differentiate
both in vitro and in vivo. Also an inverse relationship was
found to exist between cyclin D1 and cyclin D3 during this
differentiation program. Agents that target cyclin D1 were
hypothesized to repress the growth of GCT cells. Different
siRNAs that target individual D-type cyclins were used to
confirm this. To test this independently, EC cells were
treated with the epidermal growth factor receptor tyrosine
kinase inhibitor, erlotinib. Growth inhibition was triggered in
both NT2/D1 and NT2/D1-R1 cells and this also decreased
cyclin D1 protein levels. Thus, cyclin D1 is a molecular target
for the treatment of GCTs and agents that target this species
should be explored, especially in cases that are resistant to
cisplatin-based chemotherapy regimens. 
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